Trial Profile

The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir
Indications HIV-1 infections
Focus Pharmacodynamics
Sponsors ViiV Healthcare

Most Recent Events

10 Dec 2015 Accrual to date is 45% according to United Kingdom Clinical Research Network record.
05 Nov 2015 Accrual to date is 36% according to United Kingdom Clinical Research Network record.
07 Oct 2015 Accrual to date is 31% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com